Which of the following is correct about the EMLA patch shown in the image below?
Q12
A patient has a history of vomiting and was given an antiemetic. The patient subsequently developed abnormal movements (likely extrapyramidal symptoms or dystonia). What medication should be given to manage these abnormal movements?
Q13
A 30-year-old male presents with a history of consuming an unknown substance. On examination, the patient has diaphoresis, headache, and features resembling acute coronary spasm. Which of the following clinical features is least likely to be present in this patient?
Q14
A child accidentally ingested a fruit from a tree while playing. After the ingestion, he presented with symptoms of restlessness, painful swallowing, photophobia, dry skin, urinary retention, and elevated body temperature. What is the most likely cause of poisoning, and what is the appropriate antidote for it?
Q15
Beta 2 receptors act via which of the following secondary messenger systems
Q16
A 68-year-old woman is brought to the emergency department by her son for altered mental status. She recently had a right knee arthroplasty and was discharged 2 days ago. Her medical history is significant for type 2 diabetes mellitus and hypertension, for which she takes metformin and hydrochlorothiazide, respectively. She also had left cataract surgery 1 year ago. Her temperature is 97°F (36.1°C), blood pressure is 99/70 mmHg, pulse is 60/min, respirations are 8/min. Her exam is notable for anisocoria with an irregularly shaped left pupil and a 1 mm in diameter right pupil. She opens her eyes and withdraws all of her limbs to loud voice and painful stimulation. Her fingerstick glucose level is 79. The patient does not have any intravenous access at this time. What is the best next step in management?
Q17
A 34-year-old woman presents to the office with weight gain despite her dietary modifications. She also says she has associated constipation and feels she has no energy. She says she often feels the ambient temperature is too cold these days. Her past medical history is insignificant. Her blood pressure is 140/85 mm Hg, the pulse is 60/min, the temperature is 36.7°C (98.0°F), and the respirations are 22/min. On physical examination, deep tendon reflexes are 1+ at the right ankle, which has a delayed relaxation phase. A hormone deficiency disorder is suspected and blood samples are sent to the lab for investigation. The laboratory report confirms the suspicion, and the patient is prescribed a synthetic hormone. How does this hormone most likely act to produce its cellular effects?
Q18
A 24-year-old man presents with a history of intermittent fever for the last 2 days. He says his episodes of fever are accompanied by shaking and chills. He mentions that his father has been recently recovered from chloroquine-resistant P. falciparum malaria, which was treated successfully with quinine. On physical examination, his temperature is 38.9°C (102°F), pulse rate is 110/min, blood pressure is 116/80 mm Hg, and respiratory rate is 18/min. Examination of his abdomen reveals splenomegaly. His blood sample is sent for the examination of the peripheral smear, which confirms the diagnosis of Plasmodium falciparum malaria. The patient is placed on treatment with oral quinine. After 5 days, the patient returns with improved symptoms of malaria but with complaints of a headache, tinnitus, nausea, and dizziness. The patient mentions that he has been taking a drug for the last 3 months to control his dyspepsia symptoms. Which of the following drugs is most likely to have caused the above-mentioned symptoms in this patient?
Q19
An 81-year-old woman is brought to the physician by her son because of worsening forgetfulness and disorientation over the past 2 years. She has to be reminded of her grandchildren's names and frequently forgets her current address. She lives with her son. She has occasional episodes of urinary incontinence. She appears well nourished. Neurologic examination shows no abnormalities; her gait is normal. Mental status examination shows mild memory impairment. She is oriented to self and place, but not to time. Which of the following is the most appropriate pharmacotherapy?
Q20
A 57-year-old woman presents complaining of feeling sleepy all the time. She reports having an uncontrollable urge to take multiple naps during the day and sometimes sees strange shadows in front of her before falling asleep. Although she awakens feeling refreshed and energized, she often finds herself ‘stuck’ and cannot move for a while after waking up. She also mentions she is overweight and has failed to lose weight despite multiple attempts at dieting and using exercise programs. No significant past medical history. No current medications. The patient denies smoking, alcohol consumption, or recreational drug usage. Family history reveals that both her parents were overweight, and her father had hypertension. Her vital signs include: pulse 84/min, respiratory rate 16/min, and blood pressure 128/84 mm Hg. Her body mass index (BMI) is 36 kg/m2. Physical examination is unremarkable. Which of the following medications is the best course of treatment in this patient?
Cholinergic/Adrenergic drugs US Medical PG Practice Questions and MCQs
Question 11: Which of the following is correct about the EMLA patch shown in the image below?
A. Adverse effect is methemoglobinemia
B. Contains bupivacaine & lignocaine
C. Eutectic mixture is used (Correct Answer)
D. 0.5% concentration of lignocaine has 50 mg in 1 gm is used
E. Requires application for at least 15 minutes for adequate anesthesia
Explanation: ***Eutectic mixture is used***
- EMLA stands for **Eutectic Mixture of Local Anesthetics**, indicating that it uses a mixture of lidocaine and prilocaine to lower their melting points, allowing them to remain liquid at room temperature.
- This liquid form enhances skin penetration, providing more effective topical anesthesia compared to individual agents.
*Adverse effect is methemoglobinemia*
- While methemoglobinemia is a potential side effect of **prilocaine**, which is part of the EMLA cream, it is usually only seen with **excessive doses** or in susceptible individuals (e.g., infants).
- Given its topical application and typical dosing, it is not the most common or direct feature associated with correct use of the EMLA patch.
*Contains bupivacaine & lignocaine*
- The EMLA patch contains **lidocaine (lignocaine)** and **prilocaine**, not bupivacaine.
- Bupivacaine is another local anesthetic, but it is not a component of the EMLA formulation.
*0.5% concentration of lignocaine has 50 mg in 1 gm is used*
- The EMLA patch typically contains a 2.5% concentration of **lidocaine** and 2.5% of **prilocaine**, meaning 25 mg of each per gram of cream.
- A 0.5% concentration would be 5 mg per gram, so the stated concentration and amount are incorrect for the EMLA formulation.
*Requires application for at least 15 minutes for adequate anesthesia*
- EMLA requires a **minimum of 60 minutes** of application time for adequate dermal anesthesia, not 15 minutes.
- For procedures on intact skin, the recommended application time is **60-120 minutes** to achieve optimal anesthetic effect.
Question 12: A patient has a history of vomiting and was given an antiemetic. The patient subsequently developed abnormal movements (likely extrapyramidal symptoms or dystonia). What medication should be given to manage these abnormal movements?
A. Hyoscine
B. Methyl dopa
C. Benzhexol (Correct Answer)
D. Cyproheptadine
E. Diphenhydramine
Explanation: ***Benzhexol***
- **Extrapyramidal symptoms (EPS)** and **dystonia** are often caused by dopamine receptor blockade, and **anticholinergic medications** like benzhexol help restore the **dopamine-acetylcholine balance**.
- Benzhexol is a **muscarinic antagonist** that effectively reduces drug-induced Parkinsonism, dystonia, and akathisia by acting centrally.
- It is the **preferred oral agent** for ongoing management of drug-induced movement disorders.
*Diphenhydramine*
- Diphenhydramine is an **antihistamine** with **anticholinergic properties** that can be used for **acute dystonic reactions**, particularly when given parenterally (IV/IM).
- While effective for acute management, benzhexol is generally preferred for **ongoing oral therapy** and has more potent central anticholinergic effects.
*Hyoscine*
- While hyoscine is also an **anticholinergic agent**, it is primarily used for preventing **motion sickness** and managing **postoperative nausea and vomiting**.
- Its efficacy in reversing acute extrapyramidal symptoms induced by neuroleptics or antiemetics is generally **less pronounced** compared to agents like benzhexol.
*Methyl dopa*
- Methyl dopa is an **alpha-2 adrenergic agonist** primarily used in the treatment of **hypertension**, especially in pregnancy.
- It works by reducing sympathetic outflow and is **not indicated** for managing extrapyramidal symptoms or dystonia.
*Cyproheptadine*
- Cyproheptadine is an **antihistamine** with **serotonin antagonist** properties, used to treat allergic reactions, appetite stimulation, and occasionally **serotonin syndrome**.
- It does not have significant anticholinergic effects that would alleviate medication-induced extrapyramidal symptoms or dystonia.
Question 13: A 30-year-old male presents with a history of consuming an unknown substance. On examination, the patient has diaphoresis, headache, and features resembling acute coronary spasm. Which of the following clinical features is least likely to be present in this patient?
A. Hypertension
B. Tachycardia
C. Hyperthermia
D. Bradycardia (Correct Answer)
E. Mydriasis
Explanation: ***Bradycardia***
- The presented symptoms of diaphoresis, headache, and coronary spasm are consistent with **stimulant intoxication** (e.g., cocaine, amphetamines).
- Stimulants typically cause **tachycardia** due to sympathetic overactivity, making bradycardia the least likely finding.
*Hypertension*
- **Stimulant intoxication** leads to increased sympathetic activity, causing **vasoconstriction** and elevated blood pressure.
- This is a common and expected finding in cases presenting with coronary spasm due to substance abuse.
*Tachycardia*
- **Sympathetic overstimulation** from an unknown substance, particularly stimulants, directly increases heart rate.
- This symptom closely aligns with the patient's presentation of diaphoresis and coronary spasm.
*Hyperthermia*
- Elevated body temperature is a frequent consequence of **stimulant overdose** due to increased metabolic activity and impaired thermoregulation.
- **Diaphoresis** (sweating) can be a compensatory mechanism for hyperthermia or a direct effect of sympathetic activation.
*Mydriasis*
- **Pupillary dilation** is a characteristic finding in sympathomimetic toxidrome caused by stimulant drugs.
- This occurs due to alpha-adrenergic stimulation of the radial muscle of the iris and is commonly seen with cocaine or amphetamine use.
Question 14: A child accidentally ingested a fruit from a tree while playing. After the ingestion, he presented with symptoms of restlessness, painful swallowing, photophobia, dry skin, urinary retention, and elevated body temperature. What is the most likely cause of poisoning, and what is the appropriate antidote for it?
A. Datura poisoning & Physostigmine (Correct Answer)
B. Yellow Oleander poisoning & Atropine
C. Datura poisoning & Pralidoxime
D. Organophosphate poisoning & Pralidoxime
E. Mushroom (Amanita) poisoning & Atropine
Explanation: ***Datura poisoning & Physostigmine***
- The symptoms of **restlessness, painful swallowing, photophobia, dry skin, urinary retention, and elevated body temperature** are classic signs of **anticholinergic toxicity**, which is characteristic of **Datura poisoning**.
- **Physostigmine** is an **acetylcholinesterase inhibitor** that increases acetylcholine levels, effectively reversing the anticholinergic effects of Datura.
*Yellow Oleander poisoning & Atropine*
- **Yellow Oleander poisoning** primarily causes **cardiac effects** (e.g., bradycardia, arrhythmias) due to cardiac glycosides, not the anticholinergic symptoms described.
- **Atropine** is an **anticholinergic agent** and would worsen the symptoms of Datura poisoning rather than being an antidote for it.
*Datura poisoning & Pralidoxime*
- While **Datura poisoning** is correct given the symptoms, **Pralidoxime** is an antidote for **organophosphate poisoning**, acting as a cholinesterase reactivator, and has no efficacy in anticholinergic toxicity.
*Organophosphate poisoning & Pralidoxime*
- **Organophosphate poisoning** presents with **cholinergic symptoms** (e.g., salivation, lacrimation, urination, defecation, GI upset, emesis, miosis, bronchospasm, bradycardia), which are opposite to the anticholinergic signs seen here.
- Although **Pralidoxime** is a correct antidote for organophosphate poisoning, the clinical picture does not support this diagnosis.
*Mushroom (Amanita) poisoning & Atropine*
- **Certain mushroom poisonings** (e.g., muscarine-containing mushrooms like *Inocybe* and *Clitocybe* species) cause **cholinergic symptoms** (salivation, sweating, miosis, bradycardia), not anticholinergic symptoms.
- While **Atropine** would be the correct antidote for muscarinic mushroom poisoning, the clinical presentation here shows anticholinergic toxicity, not cholinergic excess.
Question 15: Beta 2 receptors act via which of the following secondary messenger systems
A. Adenylate Cyclase (Correct Answer)
B. Phospholipase C
C. Guanylate Cyclase
D. Direct ion channel activation
E. Tyrosine Kinase
Explanation: ***Adenylate Cyclase***
- **Beta-2 adrenergic receptors** are G-protein coupled receptors that primarily activate the **Gs protein**.
- Activation of Gs protein leads to the stimulation of **adenylate cyclase**, which converts ATP to **cAMP**, a crucial secondary messenger for various cellular responses.
*Phospholipase C*
- **Phospholipase C** is typically activated by **Gq protein-coupled receptors**, such as alpha-1 adrenergic receptors or M1/M3 muscarinic receptors.
- Its activation leads to the production of **IP3** and **DAG**, which then trigger intracellular calcium release and protein kinase C activation, respectively.
*Guanylate Cyclase*
- **Guanylate cyclase** produces **cGMP** as a secondary messenger and is primarily associated with **nitric oxide signaling** (soluble guanylate cyclase) or **natriuretic peptide receptors** (particulate guanylate cyclase).
- This system is distinct from the adrenergic receptor pathways.
*Direct ion channel activation*
- **Direct ion channel activation** occurs in **ligand-gated ion channels**, where the binding of a neurotransmitter directly opens an ion pore without the involvement of G-proteins or secondary messengers.
- Examples include nicotinic acetylcholine receptors and GABA-A receptors, which are functionally different from the G-protein coupled **beta-2 receptors**.
*Tyrosine Kinase*
- **Tyrosine kinase** signaling is characteristic of **receptor tyrosine kinases (RTKs)**, such as insulin receptors and growth factor receptors (e.g., EGF, PDGF receptors).
- These receptors undergo autophosphorylation and initiate signaling cascades independent of G-proteins, making them distinct from **beta-2 adrenergic receptors**.
Question 16: A 68-year-old woman is brought to the emergency department by her son for altered mental status. She recently had a right knee arthroplasty and was discharged 2 days ago. Her medical history is significant for type 2 diabetes mellitus and hypertension, for which she takes metformin and hydrochlorothiazide, respectively. She also had left cataract surgery 1 year ago. Her temperature is 97°F (36.1°C), blood pressure is 99/70 mmHg, pulse is 60/min, respirations are 8/min. Her exam is notable for anisocoria with an irregularly shaped left pupil and a 1 mm in diameter right pupil. She opens her eyes and withdraws all of her limbs to loud voice and painful stimulation. Her fingerstick glucose level is 79. The patient does not have any intravenous access at this time. What is the best next step in management?
A. Forced air warmer
B. Intubate
C. Computed tomography of head without contrast
D. Orange juice by mouth
E. Intranasal naloxone (Correct Answer)
Explanation: ***Intranasal naloxone***
- The patient's **depressed respiratory rate (8/min)**, **bradycardia (60/min)**, **hypotension (99/70 mmHg)**, and **altered mental status** following recent surgery (where opioids are commonly prescribed for pain) strongly suggest **opioid overdose**.
- **Naloxone** is a rapidly acting opioid antagonist that can reverse these effects, and the intranasal route is appropriate given the lack of intravenous access.
*Forced air warmer*
- While the patient is **hypothermic (97°F/36.1°C)**, warming alone will not address the primary cause of her respiratory depression and altered mental status.
- Addressing the underlying opioid overdose is more critical for immediate stabilization than temperature correction.
*Intubate*
- Although the patient has **respiratory depression**, intubation is an invasive procedure that should be considered after less invasive measures like naloxone administration, especially if the respiratory drive does not improve.
- The patient is still withdrawing to pain, indicating some level of neurologic response, and her oxygen saturation is not given, so direct intubation might be premature.
*Computed tomography of head without contrast*
- While altered mental status can be caused by intracranial pathology, the sudden onset of symptoms coupled with the recent surgery and classic signs of opioid overdose makes a **head CT** less urgent than immediate medication to reverse potential overdose.
- The **anisocoria** could be related to prior cataract surgery (irregular pupil) rather than acute neurological insult, and the fixed 1mm pupil is concerning but reversible with naloxone if opioid-induced.
*Orange juice by mouth*
- The patient's fingerstick glucose is 79, which is within the normal range, ruling out **hypoglycemia** as the cause of her altered mental status.
- Giving fluids or sustenance by mouth to a patient with altered mental status and depressed consciousness carries a significant risk of **aspiration**.
Question 17: A 34-year-old woman presents to the office with weight gain despite her dietary modifications. She also says she has associated constipation and feels she has no energy. She says she often feels the ambient temperature is too cold these days. Her past medical history is insignificant. Her blood pressure is 140/85 mm Hg, the pulse is 60/min, the temperature is 36.7°C (98.0°F), and the respirations are 22/min. On physical examination, deep tendon reflexes are 1+ at the right ankle, which has a delayed relaxation phase. A hormone deficiency disorder is suspected and blood samples are sent to the lab for investigation. The laboratory report confirms the suspicion, and the patient is prescribed a synthetic hormone. How does this hormone most likely act to produce its cellular effects?
A. Binds to a nuclear receptor (Correct Answer)
B. Activates tyrosine kinase
C. Increases intake of iodine by thyroid cells
D. Increases cyclic adenosine monophosphate (cAMP)
E. Increases activity of phospholipase C
Explanation: ***Binds to a nuclear receptor***
- The patient's symptoms (weight gain, constipation, fatigue, cold intolerance, bradycardia, and delayed deep tendon reflex relaxation) are classic for **hypothyroidism**.
- The synthetic hormone prescribed is likely **levothyroxine** (synthetic T4), which, after conversion to T3, acts by binding to **nuclear receptors** to modulate gene expression.
*Activates tyrosine kinase*
- **Tyrosine kinase receptors** are typically activated by growth factors and insulin, triggering intracellular signaling cascades, which is not the primary mechanism for thyroid hormones.
- This mechanism involves phosphorylation of tyrosine residues on target proteins and is seen with hormones like **insulin and growth hormone**.
*Increases intake of iodine by thyroid cells*
- This describes the action of **TSH (thyroid-stimulating hormone)** on thyroid follicular cells to produce thyroid hormones.
- It is not the mechanism by which synthetic thyroid hormone exerts its cellular effects.
*Increases cyclic adenosine monophosphate (cAMP)*
- **cAMP** is a second messenger involved in signaling pathways for many hormones that act on **G-protein-coupled receptors** (e.g., glucagon, epinephrine).
- This is not the primary mechanism of action for thyroid hormones.
*Increases activity of phospholipase C*
- Activation of **phospholipase C** leads to the production of **inositol triphosphate (IP3)** and **diacylglycerol (DAG)**, which are second messengers involved in calcium signaling.
- This mechanism is characteristic of hormones like **TRH (thyrotropin-releasing hormone)** and **GnRH (gonadotropin-releasing hormone)**, not thyroid hormones.
Question 18: A 24-year-old man presents with a history of intermittent fever for the last 2 days. He says his episodes of fever are accompanied by shaking and chills. He mentions that his father has been recently recovered from chloroquine-resistant P. falciparum malaria, which was treated successfully with quinine. On physical examination, his temperature is 38.9°C (102°F), pulse rate is 110/min, blood pressure is 116/80 mm Hg, and respiratory rate is 18/min. Examination of his abdomen reveals splenomegaly. His blood sample is sent for the examination of the peripheral smear, which confirms the diagnosis of Plasmodium falciparum malaria. The patient is placed on treatment with oral quinine. After 5 days, the patient returns with improved symptoms of malaria but with complaints of a headache, tinnitus, nausea, and dizziness. The patient mentions that he has been taking a drug for the last 3 months to control his dyspepsia symptoms. Which of the following drugs is most likely to have caused the above-mentioned symptoms in this patient?
A. Famotidine
B. Ranitidine
C. Cimetidine (Correct Answer)
D. Sucralfate
E. Pantoprazole
Explanation: ***Cimetidine***
- The patient is experiencing symptoms of **cinchonism** (headache, tinnitus, nausea, dizziness) due to **quinine** treatment for *P. falciparum* malaria.
- **Cimetidine** inhibits the **CYP450 enzyme system**, which is responsible for quinine metabolism. This inhibition leads to increased **quinine levels** and enhanced toxicity.
*Famotidine*
- **Famotidine** is an H2-receptor antagonist that does not significantly inhibit the **CYP450 enzyme system**.
- It would not lead to elevated quinine levels or cinchonism.
*Ranitidine*
- **Ranitidine** is an H2-receptor antagonist that has minimal or no inhibitory effect on the **CYP450 enzyme system**.
- Therefore, it would not increase quinine levels to cause toxicity.
*Sucralfate*
- **Sucralfate** is a mucosal protective agent that forms a viscous gel, binding to ulcerated tissue.
- It does not undergo systemic absorption or interact with the **CYP450 system**, thus having no effect on quinine metabolism.
*Pantoprazole*
- **Pantoprazole** is a proton pump inhibitor that, while metabolized by CYP2C19 and CYP3A4, does not significantly inhibit these enzymes to increase quinine levels.
- It is unlikely to cause the described drug interaction.
Question 19: An 81-year-old woman is brought to the physician by her son because of worsening forgetfulness and disorientation over the past 2 years. She has to be reminded of her grandchildren's names and frequently forgets her current address. She lives with her son. She has occasional episodes of urinary incontinence. She appears well nourished. Neurologic examination shows no abnormalities; her gait is normal. Mental status examination shows mild memory impairment. She is oriented to self and place, but not to time. Which of the following is the most appropriate pharmacotherapy?
A. Acetazolamide
B. Levodopa and carbidopa
C. Thiamine
D. Galantamine (Correct Answer)
E. Perphenazine
Explanation: ***Galantamine***
- This patient presents with **progressive memory impairment** and **disorientation** over two years, suggestive of Alzheimer's dementia, even with a normal neurologic exam and gait.
- **Galantamine** is an **acetylcholinesterase inhibitor** used to treat mild to moderate Alzheimer's dementia by increasing acetylcholine levels in the brain.
*Acetazolamide*
- **Acetazolamide** is a **carbonic anhydrase inhibitor** primarily used as a diuretic, for glaucoma, or to treat altitude sickness.
- It has no role in the direct treatment of dementia and would not address the underlying cognitive decline.
*Levodopa and carbidopa*
- **Levodopa and carbidopa** are used to treat **Parkinson's disease**, which is characterized by motor symptoms like tremor, rigidity, and bradykinesia.
- The patient's neurologic examination, including gait, is normal, ruling out typical Parkinsonian features.
*Thiamine*
- **Thiamine** (vitamin B1) is used to treat **Wernicke-Korsakoff syndrome**, which is often seen in individuals with chronic alcohol abuse and presents with confusion, ataxia, and ophthalmoplegia.
- This patient's presentation does not align with Wernicke-Korsakoff syndrome, and she is described as well-nourished.
*Perphenazine*
- **Perphenazine** is a **first-generation antipsychotic** used to treat psychotic disorders like schizophrenia or severe agitation.
- There is no indication of psychosis or severe agitation in this patient; antipsychotics are generally avoided in elderly patients with dementia due to increased mortality risk.
Question 20: A 57-year-old woman presents complaining of feeling sleepy all the time. She reports having an uncontrollable urge to take multiple naps during the day and sometimes sees strange shadows in front of her before falling asleep. Although she awakens feeling refreshed and energized, she often finds herself ‘stuck’ and cannot move for a while after waking up. She also mentions she is overweight and has failed to lose weight despite multiple attempts at dieting and using exercise programs. No significant past medical history. No current medications. The patient denies smoking, alcohol consumption, or recreational drug usage. Family history reveals that both her parents were overweight, and her father had hypertension. Her vital signs include: pulse 84/min, respiratory rate 16/min, and blood pressure 128/84 mm Hg. Her body mass index (BMI) is 36 kg/m2. Physical examination is unremarkable. Which of the following medications is the best course of treatment in this patient?
A. Methylphenidate (Correct Answer)
B. Orlistat
C. Alprazolam
D. Melatonin
E. Continuous positive airway pressure (CPAP)
Explanation: ***Methylphenidate***
- The patient presents with the **classic tetrad of narcolepsy**: excessive daytime sleepiness, sleep paralysis (cannot move after waking), hypnagogic hallucinations (seeing shadows before sleep), and the urge to take multiple naps despite waking refreshed.
- **Methylphenidate** is a **CNS stimulant** and first-line pharmacological treatment for **narcolepsy**, effectively reducing excessive daytime sleepiness by increasing dopamine and norepinephrine in the CNS.
- While obesity is a risk factor for obstructive sleep apnea, the patient's **refreshed awakening** and **specific narcoleptic symptoms** (sleep paralysis and hallucinations) make narcolepsy the primary diagnosis requiring treatment.
*Continuous positive airway pressure (CPAP)*
- CPAP is the treatment for **obstructive sleep apnea (OSA)**, not narcolepsy.
- While the patient's obesity increases OSA risk, OSA patients typically wake **unrefreshed**, not energized as this patient reports.
- Additionally, **sleep paralysis and hypnagogic hallucinations are NOT features of OSA**—they are specific to narcolepsy.
- Most importantly, **CPAP is not a medication** as requested in the question stem.
*Orlistat*
- **Orlistat** is a lipase inhibitor used for **obesity management**.
- While weight loss could help if OSA were present, it does not address the primary narcolepsy symptoms and is not appropriate first-line treatment for the acute presentation.
*Alprazolam*
- **Alprazolam** is a benzodiazepine used for **anxiety disorders**.
- It would **worsen daytime sleepiness** and is contraindicated in patients with sleep disorders as it depresses the CNS and can worsen both narcolepsy and potential sleep apnea.
*Melatonin*
- **Melatonin** regulates the **sleep-wake cycle** and is used for insomnia or circadian rhythm disorders.
- It does not treat excessive daytime sleepiness, sleep paralysis, or hypnagogic hallucinations characteristic of narcolepsy.